Autopsy report · NCT01067144
Stanford Accelerated Recovery Trial (START)
Cause of deathFutility
“Trial met futility stopping point”
Life of this trial
- Registered 3 months before it started.
- Ran for about 6 years 2 months before it stopped.
- 422 participants enrolled.
- Results were posted on the registry 1 year 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Conditions
- Pain; Breast Cancer; Lung Cancer
- Interventions
- Gabapentin; Lorazepam (active control); Placebo (inactive)
- Participants
- 422
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
“Trial stopped for futility” - An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
“An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility” - The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis
“The trial was terminated early due to futility in reaching the primary endpoint.” - Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer
“The trial was stopped for futility in view of the results of the anticipated analysis” - Hypothermia After In-hospital Cardiac Arrest
“interim analysis with stopping for futility”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.